A uniform definition of clinical suspicion of T-cell-mediated rejection (TCMR) in liver transplantation (LT) is needed to homogenize clinical decisions, especially within randomized trials. This multicenter study included a total of 470 primary LT recipients. The derivation cohort consisted of 142 patients who had clinically driven liver biopsies at any time after LT. The external validation cohort included 328 patients who underwent protocol biopsies at day 7-10 after LT. The rates of moderate-severe histological TCMR were 33.8% in the derivation cohort and 43.6% in the validation cohort.
| INTRODUCTION
Acute T-cell-mediated rejection (TCMR) is a frequent complication in liver transplantation (LT) and forms the primary efficacy endpoint in most randomized trials evaluating immunosuppressive drugs. The gold standard to diagnose and grade TCMR is a histological assessment using the Banff classification. 1 In the past, some institutions implemented protocol liver biopsies early after LT and reported that up to 80% of patients show histological features of TCMR. However, most of these episodes were mild and without any detrimental impact on graft survival. [2] [3] [4] Nowadays, protocol liver biopsies have been abandoned and only patients with clinical suspicion of rejection, which usually means raising transaminases otherwise unexplained, undergo a liver biopsy. However, transaminases are poor predictors of TCMR and do not mirror its histological severity. 2, 5 The agreement among transplant physicians to define clinical suspicion of rejection and to advise biopsy after LT was evaluated in a study including 100 LT patients with protocol liver biopsies at day 7. 6 The concordance among clinicians was poor or very poor in 76% of comparisons (κ coefficient <0.40), and most importantly, the concordance between clinical suspicion of rejection and the histological assessment was very poor in all cases (κ coefficient <0.30).
In randomized trials using biopsy-proven TCMR as primary efficacy endpoint, this heterogeneity in selecting candidates for liver biopsy may be translated into increased risk of bias, particularly in those with open-label design and with multicenter involvement. 7 Therefore, if protocol liver biopsies are no longer to be used, a systematic approach to select candidates for liver biopsy according to their individual risk of moderate-severe TCMR is mandatory. This method should be accurate, reproducible, and based on routine parameters whenever possible. In addition, it should not include information regarding immunosuppression, so it can be implemented in randomized trials without any confounding effect.
Although previous studies have identified some clinical predictors of TCMR, such as younger age, low MELD score, underlying autoimmune liver disease, elevated blood eosinophils count, and vitamin D deficiency, 2, 5, 8, 9 they are not sufficiently validated to guide clinical decisions. Biomarkers and immune function assays have been proposed, but again results are contradictory and they are not widely available. [10] [11] [12] [13] [14] [15] [16] [17] Within this clinical scenario, the aims of this study were as follows:
(i) to identify independent predictors of histological TCMR among routine clinical and laboratory parameters, and (ii) to design and validate an objective method to select patients at increased risk of TCMR after LT, and thus able to homogenize the selection of candidates for liver biopsy both in randomized trials and clinical practice.
| PATIENTS AND METHODS

| Study design, patients, and variables
This is a retrospective multicenter study including 470 adult primary LT patients who subsequently underwent a liver biopsy.
Patients were considered for inclusion if they had at least two determinations of complete blood count and liver tests (ie, transaminases, bilirubin and cholestatic parameters) within the 4 days prior to liver biopsy. Exclusion criteria were as follows: multiorgan transplantation, HIV infection, ongoing vascular/biliary complications, treatment with boluses of steroids 1 month prior to liver biopsy and primary immunosuppression not based on tacrolimus.
Although concomitant immunosuppressive drugs were allowed, patients with cyclosporine-based immunosuppression were excluded to increase homogeneity. Cyclosporine-based protocols are seldom used nowadays given the increased risk of TCMR and graft loss as compared with tacrolimus. 18 Included patients were divided in two cohorts: (i) a derivation cohort, which consisted of 142 pa- All liver biopsies were systematically evaluated to diagnose and grade acute TCMR according to the Banff schema, which is based on the presence of mixed mainly portal inflammation, endotheliitis, and bile duct damage and classifies TCMR as none/indeterminate, mild, moderate, and severe. 1 Only moderate-severe histological TCMR was considered clinically significant for this study, as mild TCMR does not require treatment in most cases and its prognostic impact is negligible. 7 In the derivation cohort, liver biopsies were indicated at any time after LT by the responsible transplant clinician in each center, either because of clinical suspicion of rejection, or under any other indication (mainly graft dysfunction or suspicion of hepatitis C recurrence). In the validation cohort, liver biopsies were scheduled between days 7-10 post-LT irrespective of graft function. A multicentre population with clinically driven liver biopsies is "a priori" more heterogenous, whereas a cohort with protocol liver biopsies is expected to be more uniform and closer to the gold standard to diagnose TCMR. Therefore, the former population was used as a derivation cohort while the later served as validation. In both cohorts, liver biopsies were performed percutaneously, except for patients with abnormal coagulation parameters, in whom the transjugular approach was preferred. 
| Statistical analysis
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| Sample size calculation
The minimum sample size required was calculated using EPIDAT ® 3.1 (Xunta de Galicia, Spain). The following assumptions were made: Under these premises, the minimum sample size required was n=127 (n=142 after applying Yates' correction). In this study, the derivation cohort included 142 patients and the validation cohort comprised 328 patients.
| RESULTS
| Descriptive study
A descriptive evaluation of both derivation and validation cohorts is shown in Table 1 . Both cohorts were comparable in terms of age, Regarding biochemical parameters on the day of the liver biopsy, the derivation cohort was characterized by increased levels of AST, ALP, and GGT, but lower eosinophils count, INR, and creatinine, as compared with the validation cohort. In the derivation cohort, transaminases and cholestatic parameters were stable within the 4 days prior to liver biopsy (ie, relative delta change close to 100%). In the validation cohort, transaminases were decreasing (ie, relative delta change <100%) while cholestatic parameters were rising (ie, relative delta change >100%) within the same timeframe, as it would be expected at day 7-10 after LT.
| Risk factors of histological moderate-severe TCMR in the derivation cohort
The histological evaluation of 142 included patients showed indeterminate/none TCMR in 71 patients (50%), mild TCMR in 23 patients 
| Validation of risk factors of moderate-severe TCMR in a protocol biopsy population
Among 328 patients with protocol liver biopsies at day 7-10 after 78-221]; P=.044). Some of the optimal thresholds for risk factors had to be adapted to the early phase after LT, which is characterized by a particular biochemical profile consisting in a progressive improvement of the liver graft function and variable cholestasis related to ischemia-reperfusion injury. The threshold remained unchanged for serum bilirubin on the day of the liver biopsy (ie, >4 mg/dL), but had to be increased for relative delta change in serum bilirubin within the 4 days prior to liver biopsy, which was placed at >130%, and for absolute eosinophils count on the day of the liver biopsy, which was >0.40×10 9 . According these thresholds, 40 patients (12.2%) had 0 risk factors, 97 patients (29.6%) had one risk factor, 114 patients do not provide information about liver function, and they are poor markers of TCMR. 2 The ambiguous meaning of rising transaminases after LT is responsible for the lack of agreement to diagnose TCMR among clinicians, 6 and may introduce bias in randomized trials, 7 thus hampering the path toward minimal immunosuppression and tolerance. In this study, a simple and objective model based on routine biochemical parameters was able to identify patients at increased risk of moderate-severe histological TCMR to undergo a liver biopsy.
Many studies have evaluated the role of noninvasive biomarkers of TCMR among serum parameters of inflammation 11, 17, 20, 21 or mediators of T-cell activation. 10, 22 Unfortunately, none of these biomarkers has been implemented hitherto because of their complexity, lack of reproducibility/validation, inaccuracy, or costs. 15, 23 Regarding conventional liver tests, a standardized methodology to select candidates for liver biopsy after LT has been seldom attempted and never fully accomplished. A recent systematic review of randomized controlled trials in LT published from 2007 to 2015 revealed that only two studies of 30 (6.7%) used predefined criteria to select candidates for liver biopsy. 7 In one study, the indication of liver biopsy relied on subjective symptoms including fever, malaise, back or abdominal pain, tenderness or enlargement of the liver, or change in bile color, with or without rapid increase in transaminases (no thresholds defined). 24 The second randomized trial considered patients at clinical suspicion of TCMR if they had rising transaminases among three consecutive test results (elevated >1.5 times above the baseline) or serum bilirubin elevated by >0.3 mg/dL from baseline. 25 Although less ambiguous, these latter criteria were based on opinion of experts and cutoffs were established arbitrarily. In large observational series, autoimmune liver disease, younger recipient age, eosinophilia, and vitamin D deficiency, among others, were identified as risk factors for TCMR after LT, but it is unclear how to combine this information to obtain an individualized risk assessment in each patient. 2, 5, 8, 9 A multivariate logistic regression model based on 100 LT patients with early protocol liver biopsies combined age, pre-LT MELD score, blood eosinophils count, and tacrolimus trough concentrations prior to liver biopsy. 6 However, the model lacked external validation and was hampered by its complex calculation. The methodology proposed in the present study to select candidates for liver biopsy is simple, rationale, and objective. Although restricted to patients under tacrolimus-based immunosuppression, which currently form the vast majority among the LT population, the model is independent from trough concentrations and comedications.
Its components or risk factors are routine laboratory tests, dynamic, and widely available. Their ability to mirror progressive graft dysfunction or spontaneous improvement is well established in clinical practice, but optimal thresholds were unknown, leading to a significant heterogeneity in selecting patients to liver biopsy. The present study provides cut-offs for bilirubin and blood eosinophils at different timepoints after LT, thus allowing for a more objective and homogenous assessment. The potential utility of the model to monitor response to boluses of steroids was not analyzed in the present study and requires further investigations.
The model based on risk factors was tested in two different clinical scenarios. The derivation cohort consisted in "a priori" more heterogeneous and multicentre population of patients with clinically driven liver biopsies obtained at any time after LT. In this setting, lingered to current routine clinical practice, the presence of ≥2 risk factors had fourfold increased rates of moderate-severe TCMR. There were only nine false-negative patients, and all of them had one risk factor.
Noteworthy, in absence of risk factors, no patient had moderatesevere TCMR. The model was then investigated within a larger population with protocol liver biopsies at day 7-10 after LT, which may F I G U R E 2 Rates of moderate-severe histological T-cell-mediated rejection according to the number of risk factors identified (ie, increased serum bilirubin, rising bilirubin, and increased absolute eosinophils count) be considered as more homogeneous and closer to the gold standard.
External validation in larger cohorts is often desirable, as it allows to recalibrate the model to different circumstances, and to adapt thresholds. 26 The model based on risk factors was an independent predictor of moderate-severe TCMR in the protocol biopsy evaluation, but negative predictive values were lower, and up to 1/3 of patients with 0 or one risk factor had moderate-severe TCMR. These unnoticed episodes of histological TCMR early after LT without graft dysfunction are thought to have limited prognostic relevance 27 and should not motivate the use of more intense immunosuppression. 2, 28 Therefore, although the model would not select these patients for liver biopsy, as they are not within the current clinical scenario, this may not form a significant limitation.
The present model is not a diagnostic test per se, and it is not intended to waive liver biopsies. Empirical therapy of TCMR without histological confirmation should be strongly discouraged, even among patients with three risk factors. To the contrary, the applicability of the model relies on its capacity to homogenously select patients at "a priori" high risk of TCMR to undergo liver biopsy. This strategy would solve the current lack of agreement to define clinical suspicion of TCMR, 6 and it may contribute to reduce variability both in randomized trials and in clinical practice. The derived nomogram would ease the clinical decision-making process at the bedside and would allow for an informed decision to individually advise liver biopsy.
The independent analysis of this model with much alike results in two contrasting clinical scenarios, as they are clinically driven liver biopsies and early protocol biopsies, reinforced its external validity.
Although serum bilirubin had identical thresholds for both, derivation and validation cohorts (ie, >4 mg/dL), cutoffs of relative delta bilirubin and eosinophils count had to be adapted to the early phase after LT in the validation cohort. While any worsening of serum bilirubin was considered a risk factor in long-term stable patients, a more pronounced increase by >30% of serum bilirubin was required early after LT. In other words, a mild increase in serum bilirubin (<30%) does not translate into a significant risk of TCMR early after LT, but should be considered a risk factor if it occurs thereafter. On the other hand, blood eosinophils count may be physiologically increased in the early postoperative phase. Although the underlying reasons are eluding and more likely multifactorial, this finding is not surprising given the wellrecognized role of eosinophils in tissue remodeling, inflammation and foreign-body reaction. 29 In the present study, blood eosinophilia was defined >0.4×10 9 early after LT, and >0.1×10 9 thereafter.
The potential influence of confounding factors should be taken into account. The risk of TCMR is highest within the first weeks after LT and declines abruptly thereafter being extremely rare after the first year. On the other hand, recurrent hepatitis C has a later onset, but shares some histological features with TCMR, thus forming a challenging differential diagnosis even for experienced pathologists. In the present study, both factors-interval from LT to liver biopsy and hepatitis C status-were controlled in the multivariate analysis to avoid any confounding effect. Other potential confounders such as variable quality of liver biopsy specimens, lack of central pathology reading, or agreement among pathologists from different institutions could not be controlled and may have influenced negatively the accuracy of the model. Despite this, such a large and multicenter population with detailed biochemical and histological evaluation has no precedent in the literature and derived results should be used to improve the quality of randomized trials and to benefit clinical care.
In summary, rising bilirubin over 4 mg/dL and increased blood eosinophils count defined as >0.4×10 9 within the first 10 days after LT, and >0.1×10 9 thereafter, are established risk factors of moderate-severe TCMR, whereas transaminases are not reliable.
While awaiting novel biomarkers, 23 the presence of more than one of these factors should motivate a liver biopsy to confirm the presence of TCMR and to establish its severity before starting targeted therapy. The implementation of this simple method would homogenize clinical practice, while decreasing the risk of bias in randomized controlled trials evaluating immunosuppression and using TCMR as the primary efficacy endpoint.
